Form 6-K ARGENX SE For: Dec 15

Go back to Form 6-K ARGENX SE For: Dec 15

Guggenheim on argenx SE (ARGX): 'Long-term Growth Thesis Intact'

December 15, 2025 10:25 AM UTC

Guggenheim analyst Yatin Suneja reiterated a Buy rating and $1,085.00 price target on argenx SE (NASDAQ: ARGX).

The analyst comments "We caught up with ARGX following today's announcement regarding the discontinuation of efgartigimod's (anti-FcRn) thyroid eye disease (TED) pivotal study due to futility, which we view as reflective of the specific indication biology with minimal read-across to the Graves'... More